

PII: S0040-4039(96)02264-2

A Short Synthesis of an Important Precursor to a New Class of Bicyclic β -Lactamase Inhibitors

John R. Bellettini and Marvin J. Miller*


Department of Chemistry and Biochemistry University of Notre Dame Notre Dame, IN 46556, USA

Abstract: A short synthesis of an important precursor to known bicyclic β -lactamase inhibitors is described. The synthesis uses commercially available *trans*-3-hydroxy-L-proline 1. Protection of the amino group followed by formation of the hydroxamate and cyclization using Mitsunobu conditions afforded bicyclic β -lactam 4 in three steps in 53% overall yield. Copyright © 1996 Elsevier Science Ltd

The emergence of resistance by bacteria to many of the currently used β -lactam antibiotics has led the scientific community to search for new and effective antibacterial agents and inhibitors of β -lactamase enzymes that are responsible for most resistance.¹ Recently workers at F. Hoffmann-LaRoche have reported the synthesis and biological evaluation of a variety of bicyclic β -lactams 5 and 6.² These bicyclic β -lactams were shown to have activity against the class C β -lactamases. We were particularly interested in synthesizing a precursor to these bicyclic β -lactams using the hydroxamate-mediated cyclization approach developed previously in our laboratory.³ We reasoned that we should be able to quickly and efficiently construct a precursor to these bicyclic β -lactams from commercially available *trans*-3-hydroxy-L-proline 1 (Fluka).

The amine of *trans*-3-hydroxy-L-proline 1 was protected by treatment with Boc anhydride to afford 2 in 92% yield. The carboxylic acid was then coupled with O-benzylhydroxylamine using the water soluble carbodiimide 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide (EDC) to afford hydroxamate 3 in 67% yield. Finally, the hydroxamate was cyclized using Mitsunobu conditions (diethylazodicarboxylate, PPh₃)⁴ to afford bicyclic β -lactam 4 in 86% yield. We anticipated that the cyclization would afford the N-cyclized product 4 over the carbonyl O-cyclized product based upon precedent from our previous work.³ However, we had never before attempted to form a bicyclic system using the Mitsunobu conditions. The structure of the cyclization product was indeed confirmed to be 4 by X-ray crystallography indicating that the N-cyclized product was the exclusive cyclization product.

In summary, bicyclic β -lactam 4 was synthesized in three steps with an overall yield of 53%.⁵ The previous route to bicyclic β -lactam 4 required 12 steps with an overall yield of 1.3%.^{2a} Bicyclic β -lactam 4 can be used for the synthesis of a large number of important β -lactamase inhibitors. We are currently investigating the preparation of other bicyclic β -lactams from intermediate 4 for use as β -lactamase inhibitors.



Acknowledgments: We appreciate the use of the NMR facilities of the Lizzadro Magnetic Resonance Research Center at Notre Dame. We wish to thank Dr. Maoyu Shang for the X-ray structure determination of compound 4. J.R.B. wishes to thank the Upjohn Co. for the Upjohn Fellowship Award for the spring semester of 1995, the Rohm and Haas Co. for the Rohm and Haas Graduate Fellowship in Chemistry for the fall 1995 and spring 1996 semesters, and Lubrizol for the Lubrizol Fellowship for the fall 1996 and spring 1997 semesters. We also gratefully acknowledge Eli Lilly and Co. and the NIH for providing partial financial support of this research.

References and Notes

- 1. Davies, J. Science 1994, 264, 375-382.
- (a) Angehrn, P.; Gubernator, K.; Gutknecht, E.-M.; Heinze-Krauss, I.; Hubschwerlen, C.; Kania, M.; Page, M. G. P.; Specklin, J.-L. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy 1995, Program and Abstracts, F147. (b) Charnas, R.; Gubernator, K.; Heinze, I.; Hubschwerlen, C. European patent serial No. 0508234A2 1992.
- Miller, M. J. Acc. Chem. Res. 1986, 19, 49-56.
- 4. (a) Mitsunobu, O. Synthesis 1981, 1-28. (b) Hughes, D. L. Org. React. 1992, 42, 335-656.
- Characterization data: (2) recrystallized from EtOAc-hexanes: mp 156-157 °C; IR (KBr) 3180, 1755, 1660 cm⁻¹; ¹H NMR (500 MHz, DMSO-d₆, 90 °C) δ 1.38 (s, 9H), 1.72-1.80 (m, 1H), 1.86-1.99 (m, 1H), 3.41 (apparent dd, J = 9.0, 5.0 Hz, 2H), 3.96 (s, 1H), 4.24 (s, 1H), 5.13 (br s, 1H, D₂O exchangeable), 12.14 (br s, 1H, D₂O exchangeable); ¹³C NMR (125 MHz, DMSO-d₆, 22 °C) mixture of rotomers δ 27.94, 28.11, 31.63, 32.32, 44.16, 44.45, 67.75, 67.96, 72.79, 73.78, 78.60, 78.69, 153.26, 153.70, 172.12, 172.46; [α]²⁵D = -9.9° (c = 1, MeOH); HRMS (FAB) calcd for C₁₀H₁₈NO₅ (MH⁺) 232.1185, found 232.1190; Anal. calcd for C₁₀H₁₇NO₅: C, 51.94; H, 7.41; N, 6.06. Found: C, 51.94; H, 7.30; N, 6.08. (3) recrystallized from EtOAc-hexanes: mp 158-160 °C; IR (KBr) 3520, 3200, 1700, 1660 cm⁻¹; ¹H NMR (500 MHz, DMSO-d₆ °C °C) δ 1.38 (s, 9H), 1.68-1.76 (m, 1H), 1.91-2.01 (m, 1H), 3.35-3.47 (m, 2H), 3.87 (br s, 1H), 4.10 (s, 1H), 4.81 (s, 2H), 5.00 (s, 1H, D₂O exchangeable); ⁷³C NMR (125 MHz, DMSO-d₆, 22 °C) mixture of rotomers δ 28.02, 28.13, 31.80, 32.51, 44.38, 44.65, 66.62, 66.74, 73.27, 74.27, 76.72, 76.86, 78.65, 78.72, 128.23, 128.28, 128.73, 128.87, 135.85, 153.27, 153.68, 167.25, 167.40; [α]²⁵D = -75.2° (c = 1, CHCl₃); HRMS (FAB) calcd for C₁₇H₂₅N_{2O5} (MH⁺) 337.1763, found 337.1761; Anal. calcd for C₁₇H₂₄N_{2O5}: C, 60.70; H, 7.19; N, 8.33. Found: C, 60.61; H, 7.03; N, 8.27. (4) recrystallized from hexanes: mp 88-89 °C; *R*₇0.39 (2:3 EtOAc:hexanes); IR (KBr) 1770, 1685 cm⁻¹; ¹H NMR (600 MHz, DMSO-d₆, 45 °C) δ 1.39 (s, 9H), 1.58-1.67 (m, 1H), 1.85 (apparent dd, J = 13.8 Hz, 6.0 Hz, 1H), 3.00 (ddd, J = 11.4, 11.4, 6.0 Hz, 1H), 3.74 (apparent t, J = 10.8, 9.0 Hz, 1H), 4.97 (d, J_{AB} = 11.4 Hz, 1H), 7.35-7.44 (m, 5H); ¹³C NMR (150 MHz, CDCl₃) mixture of rotomers δ 25.37, 26.09, 28.24, 43.39, 43.80, 63.40, 64.25, 64.41, 78.27, 80.69, 128.69, 129.14, 135.19, 153.35, 162.12, 162.56; [α]²⁵D = -214.9° (c = 1, CHCl₃); HRMS (FAB) calcd for C₁₇H₂₃N₂